Wednesday, 17 Oct 2018

You are here

Biosimilar Data at #EULAR2018

Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.

Abstract THU0222 reported data on 143 patients from a single clinic, ~50% had RA, and multi-switching between the etanercept originator and the biosimilar had no effect on retention of etanercept. In fact there may have even been a small protective effect of multi-switching on etanercept retention. Now it’s a single centre and its observational data so must be treated with a degree of caution but it’s an interesting result.

Another study from a large UK centre looked at the rate of flare after changing from the originator to the biosimilar and for etanercept found 4 out of 63 with RA flares after the change and 2 of 19 with SpA and 2 of 19 with PsA. For the infliximab biosimilar the flare rates was 2-4% across indications. Their conclusions were that the rate of flares was low and this supported single switch (THU0204)

Data from the TURKBIO registry on 614 patients showed that Remsima the infliximab biosimilar had better retention rates than Remicade over 5 years (THU 0218). There is also RABBIT registry data using Kaplan-Meier estimates showed that patients who were bionaive and were commenced on both the originator and biosimilar etanercept. The SB4 biosimilar (n = 250) was stopped around half the rate (14%) and the etanercept originator (n = 317) (THU0192).

So there seems to be an enlarging amount of data that is reassuring around switching patients to biosimilars and drug survival on biosimilars. But it is important to remember that registry and observational data has limitations so care has to be taken to put excessive weight on these types of results.

Add new comment

More Like This

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.